Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Covington
Dow
Harvard Business School
Colorcon
UBS
Cerilliant
Chubb
Express Scripts
Moodys

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,110,225

« Back to Dashboard

Which drugs does patent 8,110,225 protect, and when does it expire?

Patent 8,110,225 protects RYANODEX and is included in one NDA.

This patent has eight patent family members in five countries.
Summary for Patent: 8,110,225
Title:Treatment using dantrolene
Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
Inventor(s): Anderson; David (Ashland, VA), Cameransi, Jr.; Benjamin G. (Georgetown, SC), Conklin; Vincent M. (Richmond, VA)
Assignee: Lyotropic Therapeutics, Inc. (Ashland, VA)
Application Number:12/717,588
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process; Use;

Drugs Protected by US Patent 8,110,225

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,110,225

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,603,840 Treatment using dantrolene ➤ Subscribe
7,758,890 Treatment using dantrolene ➤ Subscribe
8,604,072 Treatment using dantrolene ➤ Subscribe
9,789,090 Treatment using dantrolene ➤ Subscribe
9,271,964 Treatment using dantrolene ➤ Subscribe
8,685,460 Treatment using dantrolene ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,110,225

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004262507 ➤ Subscribe
Canada 2516667 ➤ Subscribe
European Patent Office 1435781 ➤ Subscribe
European Patent Office 1603513 ➤ Subscribe
Japan 2007525439 ➤ Subscribe
Japan 4880449 ➤ Subscribe
World Intellectual Property Organization (WIPO) 03000057 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2005013919 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Citi
Teva
Novartis
Baxter
Julphar
Federal Trade Commission
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot